Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai.

This cohort study analyzed data from 48,243 patients with SARS-CoV-2 BA.2 infection in Shanghai. The primary exposure was nirmatrelvir-ritonavir, with the main outcome being viral production reduction. The study did not report a specific comparator group or follow-up duration. Structural identifiability challenges inherent in analyzing sparse real-world data were noted as a primary limitation.

Regarding main results, nirmatrelvir-ritonavir was associated with an approximate 55% average reduction in viral production. Treatment efficacy was observed to be higher in vaccinated individuals compared to unvaccinated counterparts. Conversely, efficacy appeared reduced in older adults. However, absolute numbers, p-values, or confidence intervals were not reported for these subgroup analyses.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and general tolerability, were not reported in the available evidence. The study authors highlighted that age-related differences in efficacy depend on assumptions about early viral kinetics. Funding sources and potential conflicts of interest were not reported.

The practice relevance of these findings is to inform antiviral optimization and personalized treatment strategies. Clinicians should recognize that the observed associations are based on observational data with specific methodological constraints. Causal language is avoided due to the study design and lack of reported causality notes.